Bullish indicating open at $55-$60, IPO prices at $37
In a recent transaction, Christopher Ross MacLeod, a director at Zomedica Corp. (NYSE:ZOM), purchased 143,000 shares of the company’s common stock. The shares were acquired at a price of $0.059 each, totaling approximately $8,437. According to InvestingPro data, the stock is currently in oversold territory and shows high price volatility, with the company maintaining a strong balance sheet holding more cash than debt. This acquisition increases MacLeod’s direct ownership in the company to 143,000 shares. Zomedica, based in Ann Arbor, Michigan, is involved in the pharmaceutical preparations industry. While the company has yet to achieve profitability in the last twelve months, InvestingPro analysis reveals 11 additional key insights about the company’s potential, available to subscribers.
In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported its fourth-quarter 2024 earnings, revealing a revenue of $7.9 million, which represents an 8% increase compared to the previous year. Despite recording a net loss of $7.2 million, the company maintained strong gross margins and ended the year with $71.4 million in liquidity. The earnings report highlighted that Zomedica achieved record full-year revenue of $27.3 million. The company’s strategic focus on expanding its presence in the veterinary market has contributed to its growth trajectory. Analyst firms, such as Noble Capital Markets, have shown interest in Zomedica’s product rollouts and market strategies. Additionally, Zomedica has been exploring international expansion opportunities, having received CE markings for its products, allowing sales in the EU and other regions. The company also announced a distribution agreement for Betagel, a hemostatic gel, which expands its product portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.